BioMarin (BMRN) director Athena Countouriotis receives 7,490-share RSU grant

Rhea-AI Filing Summary

BioMarin Pharmaceutical director Athena Countouriotis reported a routine equity compensation grant. On June 2, 2026, she acquired 7,490 shares of common stock in the form of restricted stock units, with no purchase price involved. Following this award, she directly holds 21,040 common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Countouriotis Athena

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,490	$0.00	--

Holdings After Transaction: Common Stock — 21,040 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 7,490 shares Price per share: $0.00 Shares held after grant: 21,040 shares

3 metrics

RSU grant size 7,490 shares Restricted stock units granted on June 2, 2026

Price per share $0.00 Compensation grant; price not applicable

Shares held after grant 21,040 shares Total direct common stock holdings following transaction

Key Terms

Restricted stock units, Form 4, Grant, award, or other acquisition

3 terms

Restricted stock units financial

"Restricted stock units granted on June 2, 2026. Price not applicable."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Countouriotis Athena

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		A		7,490	A	$0(1)	21,040	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units granted on June 2, 2026. Price not applicable.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BioMarin (BMRN) director Athena Countouriotis report?

Athena Countouriotis reported receiving 7,490 shares of BioMarin common stock as a restricted stock unit grant. This was a compensation-related award, not an open-market purchase or sale, and was reported on a Form 4 insider filing.

When was the restricted stock unit grant to BioMarin (BMRN) director Athena Countouriotis made?

The restricted stock units were granted on June 2, 2026. This transaction date is disclosed in the Form 4, which records equity awards and other insider changes in ownership for BioMarin’s director Athena Countouriotis.

How many BioMarin (BMRN) shares does Athena Countouriotis hold after this Form 4 transaction?

After the June 2, 2026 restricted stock unit grant of 7,490 shares, Athena Countouriotis directly holds 21,040 shares of BioMarin common stock. This total reflects her direct ownership position following the reported equity award.

Did Athena Countouriotis buy or sell BioMarin (BMRN) stock on the open market?

No open-market buy or sell occurred in this filing. The Form 4 shows a grant of 7,490 restricted stock units with no price per share, indicating a compensation award rather than a market transaction involving cash.

What does the zero price per share mean in the BioMarin (BMRN) Form 4 grant?

The zero price per share indicates the 7,490 BioMarin shares were granted as restricted stock units, not purchased. The footnote explicitly states they were granted on June 2, 2026 and that price is not applicable to this award.